Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Score, Valuation & Financial Research
Arrowhead Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 28/100.
Quick answer for ARWR
Arrowhead Pharmaceuticals, Inc. currently has a Wall Street Score of 28/100. The stored market price is $70.67. Its financial score is 23/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Arrowhead Pharmaceuticals, Inc. does
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other l
ARWR financial snapshot
- Wall Street Score:
- 28/100
- Current price:
- $70.67
- Market capitalization:
- $9.95B
- Revenue:
- $669.5M
- Net income:
- $-320.0M
- Free cash flow:
- $156.9M
- Cash:
- $54.8M
- Total debt:
- $864.1M
- EPS:
- -2.24
- Financial score:
- 23/100
- Valuation score:
- 0/100
- Revenue score:
- 21/100
What stands out
- Reported year-over-year revenue growth is -0.2%.
- Free cash flow is $156.9M, showing positive cash generation.
- The balance sheet shows $54.8M of cash versus $864.1M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.1 points: ARWR decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 23/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ARWR
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.